Clinical and Translational Oncology

, Volume 14, Issue 3, pp 163–168

Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

Authors

  • Atocha Romero
    • Medical Oncology DepartmentHospital Clínico San Carlos
    • Medical Oncology DepartmentHospital Clínico San Carlos
  • Eduardo Díaz-Rubio
    • Medical Oncology DepartmentHospital Clínico San Carlos
  • Miguel Martín
    • Medical Oncology DepartmentHospital General Universitario Gregorio Marañón
Educational Series / Blue Series Advances in Translational Oncology

DOI: 10.1007/s12094-012-0779-1

Cite this article as:
Romero, A., Caldés, T., Díaz-Rubio, E. et al. Clin Transl Oncol (2012) 14: 163. doi:10.1007/s12094-012-0779-1

Abstract

Anthracyclines are frequently used in the adjuvant setting for breast cancer treatment since it is considered that anthracycline-based chemotherapy treatment benefits breast cancer patients. Nonetheless, these drugs are associated with severe side effects and predictive factors, for sensitivity to anthracyclines, are warranted in clinical practice. Topoisomerase 2 alpha (TOP2A) is considered to be the molecular target of these drugs. The potential predictive value of TOP2A amplification and overexpression has been extensively studied in breast cancer patients treated with anthracyclines. However, results are not conclusive. In this paper, we review some of the published studies addressing the predictive value of TOP2A as well as the cellular functions of this enzyme and its status in breast cancer tissue.

Keywords

TOP2AAnthracyclinesPredictive factorTopoisomerase

Copyright information

© Feseo 2012